Floatz logo

Encorafenib

BRAF V600K

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the BRAF V600K cohort.

Asset / SponsorPhaseRating
Binimetinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Irinotecan
M.D. Anderson Cancer Center
Phase 1CC
Cetuximab
M.D. Anderson Cancer Center
Phase 1CC
VEMURAFENIB
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Encorafenib is also rated in:

colon carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
colon adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →